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© 200? The Japan Society of Histochemistry and Cy- Estrogen-induced pituitary prolactin-producing tumors (PRLoma) in F344 rats express a high
level of vascular endothelial growth factor (VEGF) associated with marked angiogenesis and
angiectasis. To investigate whether tumor development in E2-induced PRLoma is inhibited
by anti-VEGF monoclonal antibody (G6-31), we evaluated tumor growth and observed the
vascular structures. With simultaneous treatment with G6-31 for the latter three weeks of the
13-week period of E2 stimulation (E2+G6-31 group), the following inhibitory effects on the
PRLoma were observed in the E2+G6-31 group as compared with the E2-only group. In the
E2+G6-31 group, a tendency to reduction in pituitary weight was observed and significant
differences were observed as (1) reductions in the Ki-67-positive anterior cells, (2) increases
in TUNEL-positive anterior cells, and (3) repair of the microvessel count by CD34-immuno-
histochemistry. The characteristic “blood lakes” in PRLomas were improved and replaced by
repaired microvascular structures on 3D observation using confocal laser scanning micro-
scope. These inhibitory effects due to anti-VEGF antibody might be related to the autocrine/
paracrine action of VEGF on the tumor cells, because VEGF and its receptor are co-
expressed on the tumor cells. Thus, our results demonstrate that anti-VEGF antibody exerted
inhibitory effects on pituitary tumorigenesis in well-established E2 induced PRLomas.
Key words: anti-VEGF antibody, VEGF, estrogen, prolactinoma, angiogenesis
I. Introduction
Estrogen is known to be the most important hormone
for the regulation of physiologic development and cell pro-
liferation, and has been implicated in the pathogenesis of
endocrine lesions and several types of cancers [24, 37,
46]. Estrogen can also induce tumors in a variety of animal
models, among which prolactin-producing pituitary tumors
(PRLoma) can be induced in Fischer 344 (F344) rats by
long-term estradiol (E2) treatment [34, 44, 47]. The mech-
anism by which estrogenic-agents act to promote PRL cell
proliferation and angiogenesis is not fully understood.
However, recent reports have indicated that several hor-
mones and growth factors including VEGF are expressed
in the anterior pituitary [6, 8, 45] and furthermore the dis-
ruption of dopaminergic regulation could result in the
progression of PRLoma with abnormal pituitary blood flow
and drastic changes in the anterior pituitary vasculature [9,
10, 20, 29]. Angiogenesis is an important factor for tumor
growth [21] and abnormal tumor-related vasculature has
been an effective target for anticancer therapy [12, 16,
17]. Considering the relevance of angiogenesis in tumor
development, it is expected that tumor growth could be
blocked by anti-angiogenic agents [49, 50], and the use ofMiyajima et al. 34
anti-VEGF agents to prevent tumorigenesis would intro-
duce a beneficial therapy for vascular abundant endocrine
tumors. Among the many angiogenic growth factors in-
volved, VEGF appears to play an important role in the for-
mation of the vascularity originally found in pituitary cells
[11], among which subtype VEGF-A is the most important
member in the VEGF family in stimulating peripheral circu-
latory permeability [13]. VEGF has also been demonstrated
to be involved in mediation of the proliferative effect on the
PRL cells by estrogenic action [43]. In addition, estrogen
stimulates VEGF synthesis in the tumor cells and increased
tumoral VEGF production was enhanced during the prog-
ress of E2-induced PRLoma [1, 2]. Flk-1 (known as VEGF
receptor-2) has been shown to be expressed in endothelial
cells and also is found to mediate the function of mitogene-
sis on VEGF stimulation [53]. Furthermore, dominant-
negative inhibition of Flk-1 has been found to reduce tumor
angiogenesis and growth [38] and these findings suggest
that Flk-1 plays an important role in the development of
tumor angiogenesis and growth [54]. Expression of Flk-1
has been reported to be detected in the anterior pituitary cells
and this finding supports the autocrine/paracrine func-
tions of VEGF in the rat pituitary cells [1, 53]. Increased
expression levels of VEGF and Flk-1 have been reported in
the peripheral blood of patients with pituitary tumors [30].
Anti-VEGF antibody (bevacizumab, Genentech Inc.) is
a therapeutic agent designed to inhibit tumor angiogenesis in
human cancers. The G6-31 (Anti-VEGF antibody: kindly
supplied by Genentech Inc.) used in this study has been con-
firmed to bind to both human and murine VEGF. The nature
of this antibody is known to be related to bevacizumab ther-
apy [19, 33] and this antibody has been shown to inhibit the
binding of human and murine VEGF to VEGF-receptors in
vitro and has also been shown to be effective against rat
VEGF [33]. Liang et al. reported that anti-VEGF antibody
could reduce tumor volume in xenografts in SCID mouse
after stimulation with G6-31 [33], and Korsisaari et al.
has reported the results of injection of G6-31 into the
Apc+/min line of mice, which are susceptible to developing
intestinal adenomas suppression [31]. Also, in the endocrine
system, inhibition of the growth of pituitary adenoma and
reduction in serum prolactin levels by G6-31 has been re-
ported in the MEN1 mouse model [32].
The aim of this study is to elucidate the inhibitory ef-
fects of G6-31 on the development and angiogenesis of well-
established E2-induced PRLoma. Our data suggested that
blocking of VEGF-A by G6-31 could indicate a strategy to
inhibit tumor growth not only by inhibition of angiogenesis-
dependent tumor growth, but also by inhibiting PRL cell
proliferation and enhancing apoptosis directly associated
with the autocrine/paracrine action of VEGF produced by
the tumor cells.
II. Materials and Methods
Animals
Female Fischer 344 rats, 6-wks of age, were purchased
from Charles River Co. (Kanagawa, Japan), and kept in
stainless steel bracket cages under 12-h light/dark (lights on
from 7 a.m. to 7 p.m.) and temperature (20–25°C). The
animals were maintained in animal care facilities, with
water and food supplied ad libitum. This experiment was
conducted under guidelines for the use and care of labo-
ratory animals, approved by the institutional animal care
committee of Tokai University.
Study design
The study design is shown in Figure 1. Thirty-six ani-
mals were randomly allocated to three groups based on the
body weights at 7 weeks of age, and each group consisted of
12 rats. Two groups rats were injected with 3000 μg/kg of
estradiol (E2; estradiol dipropionate: Ovahormone Depot®,
ASKA Pharmaceutical Co., Ltd. Tokyo, Japan), once a
week intramuscularly (i.m.) for 13 wks. After 10 wks of E2
dosing, one group (the E2+G6-31 group, n=12) was also
injected intravenously (i.v.) with 5 mg/kg of G6-31 (anti-
human and murine VEGF-A monoclonal antibody, kindly
supplied by Genentech Inc., South San Francisco, CA,
USA), once a week at 2 days after each E2 injection during
the last 3 wks of the 13 wk-dosing period; and the other
(E2 group, n=12) received saline (Otsuka Pharmaceutical
Inc., Tokushima, Japan) in the same manner as the G6-31
treated group. For the vehicle control group (n=12), age and
lot-matched female F344 rats were injected with sesame oil
(Sigma-Aldrich, Inc., St Louis, MO, USA) intramuscularly
instead of E2 together with saline intravenously in the same
manner as the G6-31 treatment (Fig. 1).
Anti-VEGF antibody (G6-31)
Anti-human and murine VEGF-A monoclonal antibody
(G6-31, Lot No. 11037) was kindly supplied by Genentech
Inc., South San Francisco, CA, USA. The antibody is
monoclonal antibody which reportedly binds to human and
murine VEGF-A with high affinity [19].
Tissue preparation
Pituitaries from 6 rats in each group were used for his-
tological observation and gene expression analysis while the
remaining rats in each group (n=6) were used for three-
dimensional (3D) imaging analysis of the tumor angiogen-
esis associated with tumor development by infusing FITC-
conjugated gelatin into the anterior pituitary vessels.
The animals were sacrificed following 13 wks dosing
with E2. Six rats were dissected in each group and their pitu-
itaries were collected and weighed. For gene expression
analysis small pieces were obtained from a consistent area in
each anterior pituitary. Most of the pituitary tissues from
each animal were fixed in 4% paraformaldehyde (0.1 M
phosphate buffer, pH 7.4) for histological analysis and im-
munohistochemical procedures. For histological analysis,
the fixed tissues were dehydrated and embedded in paraffin
wax, sectioned at 4 μm thickness, and stained with H&E
following standard protocols.Anti-VEGF-A mab Inhibits E2-induced PRLoma 35
Immunohistochemistry
For the immunohistochemical studies antibodies were
purchased and diluted as follows: anti-VEGF antibody (A-
20, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA,
1:50), anti-rPRL antibody (Chemicon, Millipore Corp.,
Billerica, MA, USA, 1:100), anti-Ki-67 antibody (MM-1,
Novocastra Laboratories Ltd., Newcastle upon Tyne, UK,
1:80). and anti-hypoxia inducible factor-1α antibody (HIF-
1α, Novus Biologicals, Littleton, CO, USA, 1:50), anti-
Pituitary Tumor Transforming Gene antibody (PTTG-1,
Zymed Laboratories, Inc., South San Francisco, CA, USA,
1:50), anti-CD34 antibody (C-18, sc-7045, Santa Cruz
Biotechnology Inc., 1:80) and anti-VEGFR-2 antibody
(KDR/Flk-1, A-3, Santa Cruz Biotechnology Inc., 1:50). For
VEGF, rPRL, Ki-67 and HIF-1α, staining was performed
using Histofine Simple Stain Rat MAX PO for the rat tissue
specific Simple Stain Rat MAX-PO MULTI (Nichirei Biosci-
ences Inc., Tokyo, Japan), while that for PTTG, CD34 and
VEGFR-2 was performed using CSA kit (Dako, Grostrup,
Denmark) according to the manufacturer’s instructions in
the staining kits respectively. Sections were deparaffinized
before quenching of endogenous peroxidase activity and
blocking of endogenous biotin, and then put in a micro-
wave oven in citrate buffer (pH 6.0) twice for 10 min and
left to cool at room temperature. Sections were incubated
with primary antibodies overnight at 4°C and each antibody
was used at an appropriate concentration as described
above. After incubation of the primary antibodies and using
a detection kit, the sections were incubated in 3'3-diamino-
benzidine solution (Wako Pure Chemical Industries, Ltd.,
Osaka, Japan) as a chromogen, usually for 3 min. Sections
were counter-stained lightly with hematoxylin.
Quantitative analysis of CD34-positive microvessels in the 
anterior pituitary
To evaluate the development of tumor angiogenesis in
the anterior pituitary, immunohistochemical examination for
CD34 was performed. Quantitation of the microvessels was
carried out according to the methods previously reported [3,
4, 18]. To determine the microvascular density, sections
immunostained for CD34 were first scanned under low
magnification (×40) for hot spot areas (most dense vascu-
lar staining). Microvascular density was then determined by
averaging the number of blood vessels in CD34-positive
vessels in 10 fields selected at ×400 magnification randomly
in each of the pituitary slides. Mean numbers per field were
calculated. The blood vessels were then classified into two
categories according to their size (i.e. small and large).
Blood vessels <5 μm were classified as small vessels and >5
to 10 μm were classified as large vessels. Cystic blood lakes
which were not lined by CD34-positive endothelial cells
were also counted in the same manner.
Cell proliferation
Cell proliferation in the pituitary anterior was detected
by immunohistochemical staining with Ki-67. Ki-67-
positive nuclei were counted randomly from 1000 anterior
pituitary cells in each rat pituitary in microscopic fields at
×400 magnification in each section by blinded observation.
Fig. 1. Effect of G6-31 (Anti-VEGF-A antibody) on E2 induced pituitary PRLoma in female F344 rats. E2 group: treatment protocol for E2-
induced PRLoma, at seven-week of age female rats were given E2 (i.m., once weekly) for 13 wks. E2+G6-31 group: In the same manner as the
E2 group and during the last 3 wks of E2 dosing, simultaneous use of G6-31 (i.v., once weekly) for 3 wks. Control group: Animals were treated
with sesame oil as with E2 and saline with G6-31. Details are provided in Materials and Methods.Miyajima et al. 36
Determination of apoptosis
The number of apoptotic bodies was determined with
the use of the terminal deoxynucleotidyltransferase (TdT)-
mediated dUTP nick-end labeling (TUNEL) method. An in
situ cell death detection kit (Apomark, Exalpha Biological,
Inc., Boston, MA, USA) was used according to the manu-
facturer’s instructions. The number of apoptotic cells was
counted randomly per 2000 anterior pituitary cells in
microscopic fields at ×400 magnification in each section
by blinded observation.
Three dimension imaging analysis of pituitary vessels
Three dimensional (3D) imaging observation of the
anterior pituitary microvessels was conducted using the
fluorescein-5-isothiocyanate (FITC) conjugate gelatin meth-
od [26]. For preparation of the FITC-gelatin conjugate,
the use of fluorescent dye conjugated-polypeptide was
introduced using acrylamide slab gels [51]. The high
molecular weight fluorescein-labeled dextran methods were
also reported [7]. We combined and modified these meth-
ods. Ten mg of FITC (Dojindo Laboratories, Kumamoto,
Japan) was dissolved in 1 ml dimethylsulfoxide (DMSO;
Sigma-Aldrich, Inc., St Louis, MO, USA) and mixed for
conjugation to 20% gelatin (Sigma-Aldrich, Inc.) solution
of pH 11 at 37°C for overnight. The FITC-conjugated
gelatin (FITC-gelatin) was then dialyzed in 0.01 M phos-
phate buffered saline (PBS, pH 7.4) at 37°C in the dark for
1 week. One hundred ml of the FITC-gelatin solution was
used for injection into each rat.
To demonstrate 3D images of the intrapituitary micro-
vessels using the confocal laser scanning microscopy
system (CLSM; LSM510-Meta, Carl Zeiss MicroImaging
GmbH, Jena, Germany), FITC-gelatin solution was infused
intravenously to six rats in each group. The abdominal and
thoracic cavities of the rats were dissected under diethyl
ether inhalation anesthesia. The rats were perfused with 0.1
M PBS from the left ventricle of the heart and the right atri-
um was excised to draw off the circulated fluid. After com-
plete perfusion with PBS solution, FITC-gelatin solution
was injected into the left ventricle of the heart for approxi-
mately up to 5 min through the systemic circulation from left
ventricle. After infusion of 100 ml of FITC-gelatin solution,
the rats were immediately cooled to coagulate the injected
FITC-gelatin in the microvessels for 5 min and then the wet
pituitary glands were removed and immediately fixed in
graded cold 4% paraformaldehyde (PFA) overnight (4°C).
The anterior pituitary tissues were cut into 2 mm cube
blocks, placed on 50×70-mm coverslips (Matsunami Glass,
Osaka, Japan), and mounted in 0.05 M Tris-HCl buffer.
Three dimensional images of the intrapituitary microvessels
were observed by using the CLSM. The optical tomographic
imaging (Z-images) for 3D reconstruction of the micro-
vessels was conducted using a Plan-Apochromat (×63,
water immersion, NA 1.25; Carl Zeiss MicroImaging) and
Plan-Neofluar (×10, NA 0.30; ×20, NA 0.50; Carl Zeiss
MicroImaging) objective lens. Z-directional movement for
the optical sectioning of the entire specimens was controlled
by a stepping motor unit for axial scanning at 0.5–20-μm
focus steps and in total the focus depth was about 200 μm
thickness for the specimens. The image resolution was
512×512 and/or 1024×1024 pixels (12 bits, 4096 gray
levels) and the images were stored on a hard drive.
Gene expression
Total RNA was prepared from rat anterior pituitaries
fixed in RNAlater with RNeasy kit (Qiagen; Hilden,
Germany) according to the manufacturer’s instructions.
The first strand cDNA was then synthesized from the total
RNA by reverse transcription using random hexamer primers
(Invitrogen Co., Carlsbad, CA, USA) and reverse transcrip-
tase (SuperScript III; Invitrogen Co.). Quantitative reverse
transcriptase polymerase chain reaction (qRT-PCR) was
conducted using the Taq-ManTM Gene Expression Assay
(Applied Biosystems, Foster City, CA, USA). To detect
expression of the target gene, the following TaqMan Gene
Expression Assay primers and probe mixes (Applied Bio-
systems) were used: VEGF (Vegfa, Assay ID: Rn00582935
_m1), VEGFR-2 (Kdr, Assay ID: Rn00564986_m1), PTTG
(Pttg1, Assay ID: Rn00574373_m1), HIF-1α (Hif1a, Assay
ID: Rn00577560_m1) and GAPDH (Gapdh, Assay ID:
Fig. 2. Pituitary weights and gross findings. Relative pituitary
weights were calculated as mg/100g. (A) Tendency to reduction in
pituitary weights was seen in the E2+G6-31 group. However there
were no significant differences between the E2 and E2+G6-31
groups. The gross features of 3 rats in each group. These pituitaries
were immediately fixed in 4% paraformaldehyde solution after
sampling. In the E2+G6-31 group, the pituitaries were smaller and
their pale color suggested decreased vascularity compared to that in
the E2 group.Anti-VEGF-A mab Inhibits E2-induced PRLoma 37
Rn01462662_g1). Reactions were carried out using the
Applied Biosystems 7300 Real-time PCR system and the
gene expression levels of the target gene in each sample
were determined by the relative quantification method
using the GAPDH level as an endogenous control.
Statistical analysis
The results are expressed as means±S.D. Comparisons
of the individual groups were tested for statistical signifi-
cance using Student’s t-test. All statistical tests were two
sided and P<0.05 was considered to be statistically signifi-
cant.
III. Results
Pituitary weights and Gross findings of E2-induced PRLoma 
and inhibition by G6-31
After 13 wks of E2 treatment, rat PRLomas developed
macroscopically and the relative pituitary weights were sig-
nificantly increased compared to the pituitaries of the vehi-
cle control group. On the other hand, the relative pituitary
weights in the E2+G6-31-group were decreased compare to
those of E2 group although the difference between the
groups was not statistically significant (Fig. 2A). In the
gross findings in the 4% PFA-fixed pituitaries, a diffuse dark
reddish appearance was seen in the E2 group (Fig. 2B).
Fig. 3. Histopathological findings for pituitary PRLoma in F344 rats, sectioned stained with H&E (A, B, D, E, G and H) or immunohistochem-
istry for CD34 as an endothelial marker (C, F and I). Animals in the control group (A to C) or E2 only group (D to F) or E2+G6-31 group (G to
I). Distended blood vessels and cystic blood lakes are frequently seen in the E2 induced PRLoma in the E2 group (D to F). Bar=100 μm (A, D,
G) and 50 μm (B, C, E, F, H and I). J to L: Quantitative examination of the vascular counts in PRLoma; the number of vessels was counted
histologically from CD34-stained sections, for small vessels (J), large vessels (K), and CD34-negative blood lakes. **: P<0.01, E2 versus
E2+G6-31 group.Miyajima et al. 38
However, in the E2+G6-31 group, the pituitaries were
smaller and their pale color suggested decreased vascularity
compared to that in the E2 group (Fig. 2B).
Histopathology and CD34-positive microvessels
H&E-stained sections of the anterior pituitaries in the
E2 group revealed hyperplastic PRL cells and many dilated
blood vessels (Fig. 3D and 3E) compared to the features in
the control group (Fig. 3A and 3B). In the E2+G6-31 group,
hyperplastic PRL cells were decreased in size and the abun-
dance of the dilated blood vessels was primarily diminished
with small sized vessels being increased to some extent
(Fig. 3G and 3H).
The number of CD34-positive blood vessels was evalu-
ated by microscopic counting. Decrease in the number of
CD34-positive small vessels and dilatation of the microves-
sels were observed in the E2 group as compared to the con-
trol group (Fig. 3C and 3F). Moreover, CD34-negative cys-
tic blood lakes not lined by endothelial cells were noticeably
increased in the E2 group (Fig. 3F). On the other hand, these
findings were observed to be absent after treatment with
G6-31 (Fig. 3I). In the CD34 immunohistochemistry, an in-
crease in the number of small blood vessels, and a decrease
in the number of large blood vessels and CD34-negative
blood lakes were observed. Significant differences were
seen in these findings in the E2+G6-31 group compared with
the E2 group (Fig. 3J, 3K, and 3L, **: P<0.01).
Cell proliferation and apoptosis
Examination of cell proliferation in the E2-induced
PRLoma showed a marked increase in the number of Ki-
67-positive cells in the pituitaries of the rats in the E2 group
as compared to the control group (Fig. 4A and 4B). The
mean labeling index (LI) of the Ki-67-positive cells was
7.2% in the E2-only treatment versus 0.8% in the control
group (Fig. 4G). In contrast, a significant decrease in the
Ki-67-staining cells was noted in the anterior lobe in the
E2+G6-31 group compared to the E2 group (E2+G6-31
group: 3.1±1.7%, P<0.05; Fig. 4C and 4G).
In the observation of apoptotic cells by TUNEL stain-
ing, a slight increase in the apoptotic index (AI) in the PRL
cells was seen in the E2 group (0.9±0.15%, Fig. 4E) as com-
pared with the control group (0.1±0.08%; Fig. 4D and 4H).
In the E2+G6-31 group, a significant increase in the AI
(1.3±0.18%) was found as compared to the E2 group
(P<0.05; Fig. 4F and 4H).
Fig. 4. Tumor cell proliferation and apoptosis in pituitary PRLoma in F344 rats; sections stained with Ki-67 (A to C) or a TUNEL method (D to
F). Counterstaining was done with hematoxylin. Bar=50 μm. G: The labeling indexes in the anterior pituitary were calculated from Ki-67
stained sections. H: The apoptotic index in the anterior pituitary was also calculated from TUNEL sections. *: P<0.05, E2 versus E2+G6-31
group.Anti-VEGF-A mab Inhibits E2-induced PRLoma 39
Expression of PRL, VEGF and VEGF-R in the anterior 
pituitary
After treatment with E2, the PRL-positive cells were
diffusely spread in the anterior lobe (Fig. 5A and 5B). In
contrast, the intensity of PRL staining and the PRL-positive
area was increased in the E2+G6-31 group compared to the
E2 group (Fig. 5C). The serum PRL levels, which were
determined by radioimmunoassay, showed high levels of
serum PRL after the 13 wk treatment with E2 (E2 group:
1843±32 ng/ml) compared to the control group (41±36
ng/ml). In contrast, there was no difference in the PRL
concentrations between the E2 and E2+G6-31 groups
(E2+G6-31 group: 2250±957 ng/ml).
With immunohistochemistry, VEGF was detected in
the cytoplasm of the rat anterior pituitary cells in all groups
(Fig. 5D, 5E and 5F), and the VEGF-positive staining area
was extended by E2-treatment in both the E2 group and the
E2+G6-31 group. The expression of VEGF mRNA was also
markedly elevated with treatment with E2. There was no sig-
nificant difference in the intensity of staining and the level of
VEGF mRNA expression between the E2+G6-31 group and
the E2 group (Fig. 5J).
Immunohistochemistry showed that Flk-1 (VEGFR-2)
was diffusely distributed in the anterior pituitary cells and
vascular endothelial cells, and its staining was observed
faintly in the control group (Fig. 5G). The Flk-1 positive
area was increased after treatment with E2, but there was no
significant difference in the intensity of the Flk-1 staining in
the pituitary cells between the E2 group and the E2+G6-31
group (Fig. 5H and 5I). In addition, Flk-1 positive staining
was not noted in the lining of the area of blood lakes ob-
served in the E2 group. On the other hand, the expression
level of Flk-1 mRNA was decreased significantly in the
E2+G6-31 group compared to the E2 group (Fig. 5K).
Expression of the pituitary tumor transforming gene (PTTG) 
and HIF-1α in the anterior pituitary
PTTG localized in the cytoplasm of the anterior pitu-
Fig. 5. Immunohistochemistry of pituitary PRLoma in F344 rats. Staining of PRL (A to C), VEGF (D to F), Flk-1 (G to I). Counterstaining was
done with hematoxylin. Bar=20 μm. J and K: Gene expression of VEGF (J) and Flk-1 (K) in pituitary PRLoma in F344 rats. The columns show
the mean value of the relative expression of VEGF and Flk-1 compared with GAPDH as an endogenous control. *: P<0.05, E2 versus E2+G6-
31 group.Miyajima et al. 40
itary cells and PTTG-positive cells were increased after
treatment with E2 (Fig. 6A and 6B). Similarly with real time
qRT-PCR, PTTG1 mRNA levels were also significantly in-
creased in the E2 group (Fig. 6G). On the other hand, in the
E2+G6-31 group a decrease in the number of positive cells
and weakened staining intensity were observed in the pitu-
itary cells (Fig. 6C). Significant decrease was also observed
in the expression levels of PTTG mRNA in the E2+G6-31
group compare to the E2 group (Fig. 6G).
The intensity of staining for HIF-1α localized in the
cytoplasm of the anterior pituitary cells and the numbers
of positive staining cells were increased in the E2+G6-31
group compared to the E2 group (Fig. 6E and 6F). However,
the expression of HIF-1α mRNA in the anterior pituitary
showed no differences between the groups (Fig. 6H)
3D image analysis of the intra-pituitary microvessels
In 3D image analysis using CLSM, the fine vascular
network structure of the anterior pituitary was seen in the
control group (Fig. 7A). On the other hand, irregular disten-
sion, excessive branching and a segmented pattern and par-
tial loss of vessels were frequently observed in the E2 group
(Fig. 7B). Compared to the control group and E2 group,
decrease in distended and segmented pattern and focal
appearance of fine microvessels in the anterior pituitary
were clearly observed in the E2+G6-31 group (Fig. 7C).
IV. Discussion
VEGF is one of the most potent and specific angiogenic
factors, and contributes to the growth of many malignant
tumors [25], including pituitary adenoma with promoting
tumor angiogenesis and angiectasis. The induction of VEGF
expression by estrogen has been demonstrated in many tar-
get organs and the role of estrogen in endocrine tissue has
been suggested as modulation of angiogenesis and vascular
permeability [13]. As E2-induced pituitary PRLoma has
shown adequate vascularization, it is expected that VEGF
contributes to the development of the increased vascularity
and resulting increased size of PRLoma [42, 52].
The monoclonal antibody against VEGF, bevacizumab,
was approved for treatment of metastatic colorectal and non-
small lung cell carcinoma, but the effect of anti-VEGF ther-
apy on endocrine tumors has not been reported in clinical
practice. The anti-human and murine VEGF-A monoclonal
antibody, G6-31, is expected to be a prospective candidate
as an anti-angiogenic agent. In this study, after simultaneous
treatment with G6-31, pituitary PRLoma induced by E2 in
female F344 rats demonstrated significant reduction in
tumor progression. Specifically, G6-31 diminished the E2-
induced Ki-67 labeling index of anterior pituitary cells,
which were considered to be mainly PRL cells. It also en-
hanced pituitary cell apoptosis and increased the number
Fig. 6. Immunohistochemistry of pituitary PRLoma in F344 rats. Staining of PTTG (A to C) and HIF-1α (D to F). Counterstaining was done
with hematoxylin. Bar=20 μm. G and H: Gene expression of PTTG (G) and HIF-1α (H) in pituitary PRLoma in F344 rats. The columns show
the mean value of the relative expression of PTTG and HIF-1α compared with GAPDH as an endogenous control. *: P<0.05, E2 versus E2+G6-
31 group.Anti-VEGF-A mab Inhibits E2-induced PRLoma 41
of microvessels with decreased blood lakes detected by
CD34 immunohistochemistry and 3D-imaging analysis of
the features of FITC injected microvessels. Blood lakes
not lined by CD34-positive endothelial cells were observed
in the E2 group and disappeared in the E2+G6-31 group.
Moreover, in the endothelial cells of fine vessels in control
group and E2+G6-31 group, there was no significant differ-
ence in the cell proliferation or the immunohistochemistry
findings, for CD34 and Flk-1. These findings were consid-
ered to be due to the suppression of angiectasis and vas-
cular permeability by the simultaneous use of G6-31.
These results suggested that VEGF-A blockade by the
anti-tumor properties of G6-31 may provide an effective
treatment for pituitary tumors in association with anti-
proliferative and pro-apoptotic actions as well as anti-
angiogenic actions and effects on microvascular permea-
bility.
It has been reported that G6-31 inhibits significant
tumor growth and suggested that the mechanism is by in-
hibited angiogenesis [33] which significantly extends the
survival of Apc+/min mice [31]. The data from these studies,
together with our data, indicate that the antitumor activity of
G-31 is related to its anti-angiogenic action.
The tumor blood vessels in the rat PRLoma are func-
tionally pathological, i.e. their size is variable and they are
excessively branched and dilated [27, 28]. In 3-D image
analysis FITC-conjugate injected pituitary vessels visual-
ized by CLSM, treatment with G6-31 provides equal prog-
nostic inhibition as bromocriptine, a dopamine agonist,
of prolactin production in lactotrophs [10, 26, 29, 35].
Furthermore antiangiogenic agents such as thalidomide [50],
and a matrix metalloproteinase inhibitor [41] are reported
to inhibit PRLoma growth based on a strategy to block
angiogenesis.
An increase in the protein level of HIF-1α was ob-
served by immunohistochemistry in the pituitaries of E2+
G6-31 group. The expression of HIF-1α has been reported
to have a strong correlation with reduced oxygen supply
and subsequent apoptosis leading to hypoxia-dependent
cell death [5]. The increase in HIF-1α expression in the
cytoplasm (Fig. 6) after treatment with G6-31 is hypoxia-
dependent in PRLoma. Under normoxic conditions, HIF-1α
levels are reduced by constant proteosomal degradation,
whereas under hypoxic conditions the HIF-1α protein
becomes stabilized. Therefore, strong staining for HIF-1α by
immunohistochemistry represents a useful marker for low-
oxygen situations such as the findings in the pituitaries in the
E2+G6-31 group, and this finding might be related to the in-
crease in apoptosis in this group. This finding was consid-
ered to be related to the pharmacological action of G6-31.
PTTG interacts with the expression of proangiogenic
growth factors and tumorigenesis with the angiogenic phe-
notype of PRLomas [22, 36, 40]. As a homolog of securine
PTTG regulates the cell cycle and higher expression of
PTTG was noted in pituitary adenomas. Experimentally,
PTTG has also been shown to be regulated by exposure to
estrogen [23, 39] and our results demonstrated that lowered
Fig. 7. 3D-image analysis using confocal laser scanning microscopy
of the pituitary vessels of PRLoma in F344 rats. Infused FITC-
gelatin into the anterior pituitary microvessels was used to show the
blood flow in the anterior lobe. These images show the control
group (A), E2 group (B), and E2+G6-31 group (C). In the control
group, fine vascular network structure of the anterior pituitary was
seen (A). On the other hand, in the E2 group irregular distension,
excessive branching and a segmented pattern and partial loss of
vessels were noted (B). In the E2+G6-31 group, decrease in dis-
tended and segmented pattern and focal appearance of fine
microvessels in the anterior pituitary were clearly observed com-
pared to the control and E2 group (C).Miyajima et al. 42
levels of PTTG were observed in the E2+G6-31 group.
Thus, this finding suggests that the inhibitory effect of
anti-VEGF antibody on estrogen dependent tumor growth
includes the inhibition of angiogenesis and the reduction of
tumor cell proliferation.
VEGFR-1 (Flt-1) and VEGFR-2 (KDR, /FLK-1) are
expressed on the cell surface of most blood endothelial
cells, whereas VEGFR-3 is largely restricted to the lym-
phatic endothelial cells. VEGF-A binds both VEGFR-1 and
VEGFR-2, while PlGF and VEGF-B interact only with
VEGFR-1. VEGF-C and VEGF-D bind VEGFR-2 and
VEGFR-3. Among them, VEGFR-1 and VEGFR-2 are
tyrosine kinase receptors that mediate the signal activity of
VEGF-A, and of these two, VEGFR-2 is the main receptor
mediating most of the endothelial cell mitogenesis, survival,
and microvascular permeability [14, 48]. Banerjee et al. [2]
demonstrated that the expression of VEGF and its receptor,
Flk-1 protein, was enhanced significantly in the pituitary
after 7 days of treatment with estrogen, and the level of gene
expression markedly accelerated during prolonged estrogen
exposure. In our study, VEGF and Flk-1 were detected in the
anterior pituitary cells by immunohistochemistry and VEGF
may function as a growth factor with autocrine/paracrine
regulation, so blocking VEGF-A could produce; (1) de-
crease in the amount of anterior cell proliferation, (2) in-
hibition of the vascular pathological features including
decrease in the cystic blood lakes and distended vessels, (3)
improvement in vascular findings in 3D imaging analysis.
In addition, since it has been reported that VEGFR-2 stimu-
lation is responsible for the induction of vascular permea-
bility by VEGF [14, 48], these inhibitory findings in the
E2+G6-31 group may be related to suppression of the
vascular permeability in E2 induced PRLoma.
In summary, our results demonstrated the effect of G6-
31 on anti-angiogenesis and tumor inhibition during the de-
velopment of estrogen-induced tumor cell proliferation and
angiectasis in the anterior pituitary (Fig. 8). The data suggest
that this experimental design using E2-induced PRLomas
could serve as a model to study the therapeutic effects of
anti-VEGF agents on vascular-rich endocrine tumors by the
effects proposed by Folkman et al. and Folkman [15, 16].
Furthermore, anti-VEGF agents could become a nonsurgical
treatment for human vascular-rich endocrine tumors.
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